bioRxiv Science⌕ Search

Biology subjects

Crisafulli, E. M.

Publications and source records attributed to Crisafulli, E. M..

2 recordsLinked to original sources

Doxycycline inhibits both apicoplast and mitochondrial translation in apicomplexan parasites

Doxycycline is a tetracycline-class antibiotic used for malarial prophylaxis and as an occasional partner drug in malaria treatment. Doxycyclines antimalarial mechanism of action is attributed to inhibiting the prokaryotic 70S ribosomes of the apicoplast, a non-photosynthetic plastid present in most apicomplexan species including Plasmodium and Toxoplasma. At lower concentrations (<5 M) doxycycline exhibits a delayed death phenotype, typical of inhibitors of apicoplast housekeeping processes. Unlike other delayed death drugs (e.g. clindamycin), doxycycline has rapid schizonticidal activity at higher concentrations (>10 M) via an unknown and apicoplast-independent mechanism. In other eukaryotes, and plausibly in Plasmodium and Toxoplasma, doxycycline inhibits mitochondrial 70S ribosomes. Here we use a mass spectrometry approach to assess steady state and turnover for apicoplast DNA encoded proteins in Plasmodium falciparum. We directly show that these proteins decrease in both abundance and synthesis following treatment with doxycycline and clindamycin. High concentrations of doxycycline, but not clindamycin, also reduced the abundance of a mitochondrial-encoded protein. Proteins encoded by the mitochondrial genome are required for the formation of complexes III and IV in the electron transport chain. We show a reduction in abundance and activity of complex IV following doxycycline treatment in Toxoplasma gondii. High doxycycline concentrations also disrupt oxidative phosphorylation in both P. falciparum and T. gondii, likely as a consequence of impaired complex III and IV formation. For the first time we directly measure apicoplast translation inhibition and characterise doxycycline as a mitochondrial translation inhibitor of P. falciparum and T. gondii.

microbiology↗

Antibiotic inhibition of the Plasmodium apicoplast decreases haemoglobin degradation and antagonises dihydoartemisinin action

The World Health Organisation (WHO) recommends artemisinin (ART) combinations for treatment of uncomplicated Plasmodium falciparum malaria. Understanding the interaction between co-administered drugs within combination therapies is clinically important to prevent unintended consequences. The WHO guidelines recommend second line treatments that combine artesunate with tetracycline, doxycycline, or clindamycin--antibiotics that target the Plasmodium relict plastid, the apicoplast. In addition, antibiotics can be used simultaneously against other infectious diseases, leading to their inadvertent combination with ARTs. One consequence of apicoplast inhibition is a perturbation to haemoglobin uptake and trafficking--a pathway required for activation of ART derivatives. Here, we show that apicoplast-targeting antibiotics reduce the abundance of the catalyst of ART activation (free haem) in P. falciparum, likely through diminished haemoglobin digestion. We demonstrate antagonism between ART and these antibiotics, suggesting that apicoplast inhibitors reduce ART activation. These data have potential clinical implications due to the reliance on--and widespread use of--both ARTs and these antibiotics in malaria endemic regions.

microbiology↗